Business Wire·Nov 12, 2026, 7:00 AM ET

Kardigan Reports Third Quarter 2026 Financial Results and Recent Business Updates

Kardigan completed enrollment in Cohort 2 of the Phase 2b danicamtiv KINSHIP-DCM trial with topline data expected in Q2 2027 while Phase 3 enrollment is underway across both cohorts.
Kardigan completed enrollment in the Phase 2b ataciguat KATALYST-AV trial, with Week 48 topline data expected in the second half of 2027.
Kardigan continues enrollment in the Phase 2b tonlamarsen KARDINAL-ASH trial, with topline data expected in the second half of 2027.
The company holds a cash position of $591.4 million as of September 30, 2026, which supports data readouts through 2027 & the initiation of Phase 3 trials for all three programs.
Research and development expenses for the quarter ended September 30, 2026, were $64.4 million compared to $49.1 million in the prior-year period.
Net loss for the quarter ended September 30, 2026, was $58.6 million compared to $60.2 million in the prior-year period.
Kristin Reinke, former vice president of finance at Google, was appointed to the Kardigan Board of Directors & as chair of the Audit Committee on September 30, 2026.
Ataciguat real-world data indicates that patients with mild-to-moderate aortic stenosis & cardiac damage are more likely to progress rapidly, informing patient selection for future Phase 3 trials.
Tonlamarsen data presented at the American Heart Association Scientific Sessions included post-hoc analyses on blood pressure lowering & machine learning predictions for response to hepatic angiotensinogen suppression.